Disease indications for selective endobronchial lung region isolation

• US 20050178389A1
• Filed: 01/26/2005
• Published: 08/18/2005
• Est. Priority Date: 01/27/2004
• Status: Abandoned Application

• Current Assignee: Pulmonx Pulmonx
• Original Assignee: Pulmonx Pulmonx
• Inventors: Fields, Antony J., McCutcheon, John, Shaw, David Peter
• Application Number:
  US11/044,875
• Publication Number:
  US 20050178389A1
• Time in Patent Office: Days
• US Class Current: 128/207.150
• CPC Class Codes: A61B 17/12036 partial occlusion
• CPC Class Codes: A61B 17/12104 in an air passage
• CPC Class Codes: A61B 17/12159 Solid plugs; being solid before insertion
• CPC Class Codes: A61B 17/12172 having a pre-set deployed three-dimensional shape methods of manufacturing A61B2017/00526
• CPC Class Codes: A61F 2/04 Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts A61F2/18, A61F2/20 take precedence; devices, other than stent-grafts, providing patency to, or preventing collapsing of, tubular structures of the body other than stent-grafts, e.g. stents A61F2/82; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95
• CPC Class Codes: A61F 2/24 Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
• CPC Class Codes: A61F 2/2476 Valves implantable in the body not otherwise provided for
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2002/043 Bronchi

Abstract

Disclosed are various disease indications and treatment methods that benefit from selective lung region isolation. A lung region is bronchially isolated by regulating the flow of fluid to and from the lung region, such as by implanting one or more bronchial isolation devices into one or more bronchial passageways that feed air to the lung region. The bronchial isolation devices can comprise, for example, one-way valves, two-way valves, occluders or blockers, ligating clips, glues, sealants, and sclerosing agents.

Claims

1. A method of treating pulmonary hypertension in a human or mammal comprising blocking fluid flow in a bronchial passageway sufficiently to reduce pulmonary hypertension.

2. The method of claim 1, wherein blocking fluid flow in a bronchial passageway sufficiently to reduce pulmonary hypertension comprises delivering a therapeutically effective quantity of a fluid-blocking material to one or more bronchial passageways to reduce pulmonary hypertension.

3. A method of treating pulmonary hypertension in a human or mammal comprising:

assessing a level of pulmonary hypertension of a patient; and

reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced.

4. The method of claim 3, wherein reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced comprises blocking fluid flow through a lung passageway until the level of pulmonary hypertension decreases.

5. The method of claim 3, wherein reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced comprises redirecting fluid flow away from a selected region of a lung until pulmonary hypertension is reduced.

6. The method of claim 3, wherein reducing fluid flow into a selected region of a lung until pulmonary hypertension is reduced comprises placing a blocking element in a bronchial passageway communicating with the lung region, the blocking element inhibiting fluid flow into the lung region without collapsing the target lung region.

7. A method of reducing pulmonary hypertension in a patient comprising:

assessing pulmonary function;

comparing the pulmonary function to an eligibility threshold; and

if pulmonary function is higher than the eligibility threshold, blocking fluid flow into a selected region of the lung;

wherein pulmonary hypertension is reduced.

8. A method of improving lung function of a patient comprising:

measuring a lung function indicator to obtain an initial value;

comparing the initial value to a threshold value; and

if the initial value is higher than the threshold value, blocking fluid flow into one or more regions of the lung sufficiently to raise the lung function indicator above the initial value.

9. A method of treating low carbon monoxide diffusing capacity of a lung (DLCO) in a patient comprising:

measuring an initial DLCO;

comparing the initial DLCO to a threshold DLCO; and

if the initial DLCO is higher than the threshold DLCO, blocking fluid flow into one or more regions of the lung sufficiently to achieve an increase in DLCO.

10. A method of treating low carbon monoxide diffusing capacity of a lung (DLCO) in a patient comprising blocking fluid flow into one or more regions of the lung to achieve an increase in DLCO without collapsing or removing the regions of the lung.

11. A method of treating tuberculosis, comprising:

bronchially isolating a lung region to reduce the delivery of oxygen to the lung region and deprive M. tuberculosis bacillus of oxygen in the lung region; and

in combination with bronchially isolating the lung region, administering a chemotherapeutic drug to the lung region.

12. The method of claim 12, wherein the chemotherapeutic drug comprises isoniazid or rifampin.

13. The method of claim 12, wherein bronchially isolating a lung region comprises implanting one or more bronchial isolation devices into a bronchial passageway that feeds fluid to the lung region.

14. The method of claim 12, wherein the bronchial isolation device comprises a one-way valve device that prevent gas from flowing in an inhalation direction and permits gas and mucus to flow in an exhalation direction.

15. A method of treating an air leak in a lung of a patient, comprising:

identifying at least one bronchial passageway that provides airflow to a region of the lung that contains the air leak;

blocking fluid flow through the identified bronchial passageway.

16. The method of claim 15, wherein blocking fluid flow through the identified bronchial passageway comprises implanting one or more bronchial isolation devices into at least one bronchial passageway that provides airflow to the region of the lung.

17. The method of claim 16, wherein the bronchial isolation device comprises a one-way valve.

18. The method of claim 15, wherein blocking fluid flow through the identified bronchial passageway comprises blocking fluid flow through a plurality bronchial passageways that provides airflow to the region of the lung.

19. The method of claim 15, wherein identifying at least one bronchial passageway comprises using a balloon catheter to successively block airflow through bronchial passageways that provide airflow to the region of the lung until an indication is observed that air is no longer flowing through the chest drain.

20. The method of claim 15, wherein identifying at least one bronchial passageway comprises:

injecting a visible dye into a pleural space of the lung;

monitoring the bronchial passageways of the lung for expectoration of dye.

21. The method of claim 20, wherein the monitoring step is performed while the patient coughs.

22. The method of claim 15, wherein identifying at least one bronchial passageway comprises:

injecting a radiographic contrast into a pleural space of the lung;

monitoring movement of the contrast through the lung with fluoroscopy or on CT scan during cough and normal breathing of the patient.